- Lyndra Therapeutics appoints Adam Sayer as President and CEO, effective immediately.
- Sayer brings operational expertise to drive forward Lyndra’s oral weekly risperidone program and other long-acting oral therapies.
Lyndra Therapeutics, a clinical-stage biopharmaceutical company focused on pioneering long-acting oral therapies, has announced the appointment of Adam Sayer as its new President and Chief Executive Officer. Sayer, who also joins the company’s Board of Directors, succeeds Jessica Ballinger, the outgoing CEO.
Sayer previously served as Chief Transformation Officer at Envision Healthcare, where he led strategy and transformation efforts. His extensive experience in healthcare operations and payer negotiations positions him well to guide Lyndra through its next phase, particularly in advancing the company’s lead asset, oral weekly risperidone (LYN-005).
“I am excited to join Lyndra at this pivotal moment for the company,” Sayer said. “Lyndra’s LYNX® platform technology has demonstrated remarkable potential to transform oral medicine delivery, and I look forward to leading this talented team as we bring the first-ever long-acting oral medicines to market.”
Lyndra’s success under Ballinger’s leadership included completing the pivotal efficacy study for LYN-005 and forming a strategic collaboration with Thermo Fisher Scientific for global clinical research and commercial manufacturing. Amy Schulman, co-founder and Executive Chair, expressed gratitude for Ballinger’s contributions, highlighting Sayer’s operational focus as crucial for the company’s continued success.